Aeglea Bio Therapeutics Inc (AGLE) CEO Buys $180,027.84 in Stock

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn bought 26,592 shares of Aeglea Bio Therapeutics stock in a transaction on Wednesday, May 22nd. The stock was purchased at an average price of $6.77 per share, with a total value of $180,027.84. Following the completion of the acquisition, the chief executive officer now directly owns 304,135 shares of the company’s stock, valued at approximately $2,058,993.95. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

NASDAQ AGLE traded down $0.07 during trading hours on Wednesday, reaching $6.85. The stock had a trading volume of 66,270 shares, compared to its average volume of 180,718. The firm has a market cap of $199.63 million, a P/E ratio of -3.22 and a beta of 0.89. Aeglea Bio Therapeutics Inc has a 52-week low of $6.31 and a 52-week high of $12.00.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04). As a group, sell-side analysts anticipate that Aeglea Bio Therapeutics Inc will post -2.19 earnings per share for the current year.



A number of large investors have recently made changes to their positions in AGLE. Aisling Capital Management LP acquired a new position in Aeglea Bio Therapeutics in the fourth quarter valued at approximately $6,506,000. Goldman Sachs Group Inc. lifted its holdings in Aeglea Bio Therapeutics by 2,182.7% in the first quarter. Goldman Sachs Group Inc. now owns 403,424 shares of the biotechnology company’s stock valued at $3,248,000 after acquiring an additional 385,751 shares during the period. Marshall Wace LLP acquired a new position in Aeglea Bio Therapeutics in the first quarter valued at approximately $3,026,000. BlackRock Inc. lifted its holdings in Aeglea Bio Therapeutics by 26.7% in the fourth quarter. BlackRock Inc. now owns 1,304,062 shares of the biotechnology company’s stock valued at $9,768,000 after acquiring an additional 275,066 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Aeglea Bio Therapeutics by 57.4% in the first quarter. Dimensional Fund Advisors LP now owns 450,591 shares of the biotechnology company’s stock valued at $3,627,000 after acquiring an additional 164,366 shares during the period. 57.21% of the stock is owned by institutional investors.

A number of brokerages have commented on AGLE. HC Wainwright began coverage on shares of Aeglea Bio Therapeutics in a report on Tuesday. They issued a “buy” rating and a $20.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Aeglea Bio Therapeutics in a report on Thursday, March 21st. They issued an “overweight” rating and a $14.00 target price for the company. Finally, ValuEngine downgraded shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Aeglea Bio Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.00.

COPYRIGHT VIOLATION NOTICE: “Aeglea Bio Therapeutics Inc (AGLE) CEO Buys $180,027.84 in Stock” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2019/05/22/aeglea-bio-therapeutics-inc-agle-ceo-buys-180027-84-in-stock.html.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Read More: How to start trading in the forex market?

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.